GlassScriptPhysician profile
Lesli E Nall
NPI 1750621561
$6,702.41
in general payments reported to CMS, 2019-2025
37 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,275 · 2022: $1,126 · 2023: $963 · 2024: $1,544 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606 · Travel and Lodging: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.07 |
| Travel and Lodging | $695.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,152.53 | 2021-2025 | Minimed 780g, Guardian Sensor (3) |
| Lilly USA, LLC | $747.11 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $541.51 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $489.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $440.69 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.33 | 2021-2025 | Jardiance |
| Dexcom, INC. | $318.98 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $256.67 | 2022-2025 | |
| Abbvie INC. | $255.27 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $217.17 | 2021-2025 | |
| Abbott Laboratories | $211.75 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $197.82 | 2021-2022 | |
| Corcept Therapeutics | $158.58 | 2024-2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $157.01 | 2022-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $151.77 | 2021-2024 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $119.97 | 2023-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $102.52 | 2023-2025 | Isturisa |
| Mannkind Corporation | $87.50 | 2022-2024 | Afrezza |
| Tandem Diabetes Care, INC. | $80.54 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Teva Pharmaceuticals USA, INC. | $76.16 | 2024-2025 | Austedo Xr, Austedo Xr |
| Nevro Corp. | $62.07 | 2021-2024 | Senza |
| Amarin Pharma, INC. | $60.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.71 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $51.37 | 2025 | |
| Lundbeck LLC | $41.82 | 2024-2025 | Vyepti |
| Cequr Corporation | $40.14 | 2025 | Cequr Simplicity |
| Beta Bionics, INC. | $39.33 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Grt US Holding, INC. | $33.74 | 2021 | |
| Kyowa Kirin, INC. | $31.91 | 2024-2025 | Crysvita |
| Grifols USA, LLC | $31.77 | 2023-2024 | Prolastin-C Liquid |
| Zealand Pharma US, INC. | $28.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.89 | 2022 | |
| Averitas Pharma INC. | $19.50 | 2023 | Qutenza |
| Endo Pharmaceuticals INC. | $19.26 | 2022 | |
| Ascensia Diabetes Care US INC. | $18.84 | 2024 | |
| Avvisto Therapeutics, LLC | $14.90 | 2024 | Cycloset |
| Antares Pharma, INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesli Nall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.